Evidence map›Paper›PMID 29484115›Full record

ArticleOncotarget2018

Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes.

Candace A Frerich, Kathryn J Brayer, Brandon M Painter, Huining Kang, Yoshitsugu Mitani, Adel K El-Naggar, Scott A Ness

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 50 citations in OpenAlex.

  1. TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2025
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Engrailed-1 Promotes Pancreatic Cancer Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  19. Article
  20. The immune response to a fungus in pancreatic cancer samples.bioRxiv : the preprint server for biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Candace A FrerichDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Kathryn J BrayerDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Brandon M PainterDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Huining KangDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Yoshitsugu MitaniHead and Neck Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adel K El-NaggarHead and Neck Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Scott A NessDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
University of New Mexico · USThe University of Texas MD Anderson Cancer Center · USUNM Comprehensive Cancer Center

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Mutations and Target Genes in Adenoid Cystic CarcinomaR01DE023222 · NIDCR · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Viswanathan Palanisamy · 2012 to 2026
$5.6M
Alternative RNA splicing and protein products in leukemia outcome (PQ11)R01CA170250 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI NESS, SCOTT A. · 2012 to 2015
$2.3M
NCI NIH HHS P30 CA118100NCI NIH HHS R01 CA170250NIDCR NIH HHS R01 DE023222
6 · The paper itself

Abstract

The relative rarity of salivary gland adenoid cystic carcinoma (ACC) and its slow growing yet aggressive nature has complicated the development of molecular markers for patient stratification. To analyze molecular differences linked to the protracted disease course of ACC and metastases that form 5 or more years after diagnosis, detailed RNA-sequencing (RNA-seq) analysis was performed on 68 ACC tumor samples, starting with archived, formalin-fixed paraffin-embedded (FFPE) samples up to 25 years old, so that clinical outcomes were available. A statistical peak-finding approach was used to classify the tumors that expressed

Indexed as

bioinformaticsbiomarkeremtpersonalized medicineprecision medicine

Identifiers

PMID29484115
PMCPMC5800907
OpenAlexW2779604980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.